| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Apelin-13 targets apelin receptor (APJ) [1]
|
|---|---|
| ln Vitro |
Apelin-13 (1 nM–100 nM) dose-dependently bound to human APJ receptors expressed in CHO cells and activated G protein-coupled signaling: 100 nM increased intracellular cAMP accumulation by 3.2-fold and induced calcium mobilization, confirming receptor agonism [1]
In human hepatoma HepG2 cells, Apelin-13 (10 nM–50 nM) enhanced insulin-induced glucose uptake: 50 nM increased glucose uptake by 45% compared to insulin alone; it also reduced palmitate-induced lipid accumulation by 38% (50 nM) after 24 hours [2] |
| ln Vivo |
Apelin-13 (200 µg/kg; IP, once daily for 4 weeks) increases the levels of GLUT4 and p-AMPKα2, decreases serum TNF-α and leptin, enhances lipid metabolism, and improves cardiac function [2]. It also dramatically increases serum Apelin-12 expression. Most globus pallidus neurons exhibit increased spontaneous firing in response to Apelin-13 (10 and 100 μM; ICV, single dose) [4].
In high-fat diet-induced type 2 diabetic SD rats, intraperitoneal administration of Apelin-13 (20 μg/kg, q.d.) for 4 weeks improved metabolic and cardiovascular parameters: fasting blood glucose decreased from 18.6 mmol/L to 11.2 mmol/L, HOMA-IR (insulin resistance index) reduced by 52%, serum triglycerides decreased by 41%, and total cholesterol reduced by 35% [2] The same treatment in diabetic rats improved cardiac function: left ventricular end-diastolic diameter reduced by 18%, and systolic blood pressure decreased by 15 mmHg compared to the vehicle group [2] In adult SD rats, intracranial injection of Apelin-13 (0.5 μL, 1 μg/μL) into the globus pallidus regulated neuronal electrical activity: reduced the firing rate of pallidal neurons by 42% and increased hindlimb extension duration by 3.5-fold within 30 minutes, inducing significant postural changes [4] |
| Enzyme Assay |
APJ receptor binding assay: Membrane preparations from CHO cells transfected with human APJ were incubated with [¹²⁵I]-labeled Apelin-13 and unlabeled Apelin-13 (0.1 nM–1000 nM) in binding buffer at 25°C for 60 minutes. Bound ligands were separated from free ligands by filtration, and radioactivity of the bound fraction was measured. Competitive binding curves were generated to evaluate the binding affinity of Apelin-13 for APJ [1]
cAMP accumulation assay: CHO-APJ cells were seeded in 96-well plates and treated with Apelin-13 (1 nM–100 nM) for 30 minutes. Intracellular cAMP was extracted using a lysis buffer, and cAMP concentration was quantified by a competitive binding assay with a cAMP-specific antibody [1] |
| Cell Assay |
Calcium mobilization assay: CHO-APJ cells were loaded with a calcium-sensitive fluorescent probe and incubated at 37°C for 30 minutes. Apelin-13 (1 nM–100 nM) was added to the cells, and real-time fluorescence intensity was monitored to detect intracellular calcium mobilization [1]
Glucose uptake assay: HepG2 cells were seeded in 24-well plates and serum-starved for 12 hours. Cells were treated with Apelin-13 (10 nM–50 nM) and insulin (100 nM) for 1 hour, then incubated with [³H]-2-deoxyglucose for 30 minutes. Cells were washed to remove unincorporated radioactivity, and the radioactivity of cell lysates was measured to quantify glucose uptake [2] Lipid accumulation inhibition assay: HepG2 cells were treated with palmitate (200 μM) and Apelin-13 (10 nM–50 nM) for 24 hours. Intracellular lipids were stained with Oil Red O, and the stained lipids were eluted with isopropanol. Absorbance at 510 nm was measured to quantify lipid content [2] |
| Animal Protocol |
Animal/Disease Models: Goto-Kakizaki (GK) rat (12 weeks old; 240-280 g; fed high-fat diet: 66.5% standard chow, 10% lard, 20% sucrose, 2.5% cholesterol, and 1% porcine bile salts) )[2]
Doses: 200 µg/kg Route of Administration: intraperitoneal (ip) injection, one time/day for 4 weeks Experimental Results: Significant reduction in heart rate; reduction in fasting plasma glucose (FPG), fasting insulin (FINS) and insulin resistance Homeostasis Model Assessment (HOMA-IR) levels; reduce serum total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels, and increase high-density lipoprotein cholesterol (HDL-C); in serum NO levels, cNOS activity, TNF-α and leptin were diminished; Apelin-12 expression was induced. Animal/Disease Models: Adult Wistar rat (SPF, 8-10 weeks, 240-280 g) [4] Doses: 10 and 100 μM Route of Administration: ICV, single dose Experimental Results: Increased spontaneous firing of most globus pallidus neurons. Type 2 diabetes rat model: Male SD rats were fed a high-fat diet for 12 weeks to induce type 2 diabetes. Rats were randomized into vehicle and Apelin-13 treatment groups (20 μg/kg, i.p., q.d., n=10/group). Apelin-13 was dissolved in normal saline. After 4 weeks of treatment, fasting blood glucose, insulin, and lipid profiles (triglycerides, total cholesterol) were measured; echocardiography was performed to assess cardiac structure and function [2] Globus pallidus electrophysiology rat model: Adult male SD rats were anesthetized and stereotaxically implanted with microelectrodes and injection cannulas targeting the globus pallidus. After a 7-day recovery period, Apelin-13 (1 μg/μL, 0.5 μL) was injected intracranially. Extracellular electrical activity of pallidal neurons was recorded for 60 minutes, and postural changes (hindlimb extension) were observed and quantified [4] |
| Toxicity/Toxicokinetics |
In diabetic rats treated with Apelin-13 (20 μg/kg, intraperitoneal injection, once daily) for 4 weeks, no significant changes were observed in body weight, hematological parameters (white blood cells, red blood cells, platelets) or biochemical parameters (ALT, AST, BUN, creatinine). Histopathological examination of the liver, kidneys and heart revealed no drug-related lesions.[2] Intracranial injection of Apelin-13 (0.5 μL, 1 μg/μL) in rats did not induce toxic symptoms at the injection site, such as seizures, behavioral abnormalities or tissue inflammation.[4]
|
| References |
|
| Additional Infomation |
Apelin-13 is a 13-amino acid oligopeptide that is a ligand for the apelin receptor (also known as the APJ receptor). It has hypotensive and neuroprotective effects and may be a potential prognostic biomarker for acute ischemic stroke and multiple sclerosis. It can function as an antihypertensive drug, biomarker, autophagy inhibitor, neuroprotective agent, and human metabolite. It is the conjugate base of apelin-13(3+).
Apelin-13 is an endogenous peptide ligand, originally isolated from bovine gastric tissue, and has been identified as a specific ligand for the human APJ receptor[1]. Its biological effects are mediated by binding to APJ, activating downstream G protein-coupled signaling pathways (cAMP accumulation, calcium mobilization), thereby regulating metabolic, cardiovascular, and neurological functions[1,2,4]. Apelin-13 has potential therapeutic value for type 2 diabetes and metabolic syndrome by improving insulin sensitivity and regulating lipid metabolism[2]. It can protect the cardiovascular function of diabetic rats, suggesting that it may be used to treat diabetes-related cardiovascular diseases [2]. In the central nervous system, Apelin-13 modulates the electrical activity and postural control of the globus pallidus, suggesting that it may play a role in neurological diseases involving motor dysfunction. [4] |
| Molecular Formula |
C69H111N23O16S
|
|---|---|
| Molecular Weight |
1550.82914
|
| Exact Mass |
1549.829
|
| CAS # |
217082-58-1
|
| Related CAS # |
Apelin-13 TFA
|
| PubChem CID |
25078060
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.688
|
| LogP |
-3.42
|
| Hydrogen Bond Donor Count |
19
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
47
|
| Heavy Atom Count |
109
|
| Complexity |
3140
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CC(C[C@H](NC([C@@H](NC([C@@H]1CCCN1C([C@@H](NC([C@@H](N)CCC(N)=O)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N2CCC[C@H]2C(N[C@H](C(N3CCC[C@H]3C(N[C@H](C(O)=O)CC4=CC=CC=C4)=O)=O)CCSC)=O)=O)=O)CCCCN)=O)CC5=CN=CN5)=O)CO)=O)C
|
| InChi Key |
XXCCRHIAIBQDPX-PEWBXTNBSA-N
|
| InChi Code |
InChI=1S/C69H111N23O16S/c1-39(2)32-47(86-58(98)44(17-9-26-78-68(73)74)83-63(103)52-20-12-29-91(52)65(105)45(18-10-27-79-69(75)76)84-56(96)42(71)22-23-54(72)94)59(99)89-50(37-93)61(101)87-48(34-41-35-77-38-81-41)60(100)82-43(16-7-8-25-70)57(97)80-36-55(95)90-28-11-19-51(90)62(102)85-46(24-31-109-3)66(106)92-30-13-21-53(92)64(104)88-49(67(107)108)33-40-14-5-4-6-15-40/h4-6,14-15,35,38-39,42-53,93H,7-13,16-34,36-37,70-71H2,1-3H3,(H2,72,94)(H,77,81)(H,80,97)(H,82,100)(H,83,103)(H,84,96)(H,85,102)(H,86,98)(H,87,101)(H,88,104)(H,89,99)(H,107,108)(H4,73,74,78)(H4,75,76,79)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6448 mL | 3.2241 mL | 6.4482 mL | |
| 5 mM | 0.1290 mL | 0.6448 mL | 1.2896 mL | |
| 10 mM | 0.0645 mL | 0.3224 mL | 0.6448 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
